Array Biopharma Inc (ARRY.OQ)
22.89USD
7:27pm GMT
$0.85 (+3.86%)
$22.04
$22.21
$22.92
$22.08
823,984
980,705
$22.92
$12.58
Latest Key Developments (Source: Significant Developments)
Array BioPharma Reports Q4 Loss Per Share $0.25
Aug 14 (Reuters) - Array Biopharma Inc
Array Biopharma Receives FDA Breakthrough Therapy Designation For Braftovi™ In Combination With Mektovi® And Cetuximab
Aug 7 (Reuters) - Array Biopharma Inc
Array Biopharma Says CHMP Recommendation For Braftovi + Mektovi Will Now Be Reviewed By European Commission
July 27 (Reuters) - Array Biopharma Inc
Array Biopharma Announces FDA Approval Of Braftovi In Combination With Mektovi
June 27 (Reuters) - Array Biopharma Inc
Array Biopharma Reports Q3 Loss Per Share $0.11
May 9 (Reuters) - Array Biopharma Inc
Aslan Pharmaceuticals buys full global commercial rights for Varlitinib
Jan 3 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS ACQUIRES FULL GLOBAL COMMERCIAL RIGHTS FOR VARLITINIB FROM ARRAY BIOPHARMA.ARRAY BIOPHARMA INC HAS GRANTED ASLAN FULL GLOBAL RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALISE VARLITINIB.ASLAN WILL MAKE AN UPFRONT PAYMENT OF $12 MILLION TO ARRAY ON SIGNATURE AND FURTHER PAYMENT OF UP TO $12 MILLION WITHIN NEXT 12 MONTHS.ASLAN WILL MAKE UPFRONT PAYMENT TOGETHER WITH UP TO US$30 MILLION OF DEVELOPMENT AND US$75 MILLION OF COMMERCIAL MILESTONES. Full Article
Array Biopharma Contributes Rights And Assets Related To Arry-797 Drug Program To Yarra Therapeutics
Dec 22 (Reuters) - Array Biopharma Inc
Array BioPharma Announces Strategic Collaboration With Pfizer
Dec 19 (Reuters) - Array Biopharma Inc
Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes
Dec 4 (Reuters) - Array Biopharma Inc
Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Nov 13 (Reuters) - Array Biopharma Inc
UPDATE 5-Lilly makes $8 bln bet on drugs for rare cancers with Loxo Oncology buy
Jan 7 Eli Lilly said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in the drugmaker's 143-year history.